Présentation de l'entreprise
HCA Healthcare, Inc. operates as a comprehensive healthcare provider in the United States through its subsidiaries, offering a diverse array of services including hospitals, ambulatory surgery centers (ASCs), freestanding emergency care facilities, urgent care centers, walk-in clinics, as well as diagnostic, imaging, radiation, and oncology therapy units. The company functions within the broader healthcare sector, specifically categorized under the medical care facilities industry, a domain characterized by high regulatory standards and essential service delivery for the population. As of the latest available data, the enterprise maintains a substantial market capitalization of $112.96 billion, generated from an annual revenue stream of $75.60 billion, while employing a workforce of 230,000 individuals. These financial figures underscore the organization's status as a massive entity within the sector, indicating deep market penetration and significant operational scale that allows for broad geographic reach and service diversification across the nation.
Santé financière
The company reported a total revenue of $75.60 billion over the trailing twelve months, resulting in a net income of $6.78 billion and an EBITDA of $15.49 billion. The substantial disparity between the $75.60 billion revenue and the $6.78 billion net income highlights a significant cost structure wherein approximately 91% of top-line revenue is consumed by operating expenses, taxes, and interest costs before reaching the bottom line. Despite these high operating costs, the entity generated $5.82 billion in free cash flow, which provides critical financial flexibility to fund capital expenditures, manage debt obligations, and potentially pursue strategic acquisitions without immediate reliance on external financing. The gross margin stands at 41.5%, reflecting the pricing power and cost efficiency in the initial procurement and delivery of medical services. The operating margin is reported at 16.3%, indicating the efficiency of the core business operations after covering direct costs. The profit margin reaches 9.0%, demonstrating the final profitability available to shareholders after all corporate expenses and taxes are deducted. Regarding liquidity and leverage, the company holds $1.14 billion in cash against a total debt load of $48.70 billion, while the debt-to-equity ratio is not disclosed in the available data. The current ratio is 0.96, suggesting that current assets are slightly below current liabilities, which points to a balance sheet that relies heavily on long-term financing rather than short-term liquidity to meet obligations. Return on assets is calculated at 12.4%, signaling that the company generates a solid return on its asset base, whereas return on equity is not disclosed in the provided metrics.
Évaluation de la valorisation
The valuation metrics reveal a trailing twelve-month P/E ratio of 17.82 and a forward P/E ratio of 15.18. The difference between the trailing and forward multiples implies that the market anticipates earnings growth that will compress the P/E multiple over the next twelve months, suggesting an expected improvement in profitability relative to the current stock price. The price-to-book ratio is listed as -18.82, a negative figure that typically indicates a discrepancy in accounting calculations or specific industry accounting standards where book value may not reflect fair market value, rather than a standard market premium discount. The price-to-sales ratio stands at 1.49, and the EV/EBITDA multiple is 10.57; these alternative valuation metrics suggest that the market values the company based on its sales scale and earnings before interest, taxes, depreciation, and amortization at a level comparable to or slightly lower than peers in the healthcare sector. Regarding price momentum, the 52-week high is $556.52 and the 52-week low is $314.43. Without the current share price explicitly defined in the data source, the relative trading position cannot be numerically calculated, but the range of $242.09 between the high and low demonstrates the volatility experienced over the last year. The beta is 1.37, indicating that the stock price is 37% more volatile than the broader market, meaning it tends to amplify market movements and carries higher systematic risk for risk-averse investors.
Growth & Income
The company demonstrated a revenue growth rate of 6.7% year-over-year, while earnings growth surged to 44.5% year-over-year. This divergence indicates that earnings are growing significantly faster than revenue, which implies improved operational leverage, cost efficiencies, or a positive mix shift within the business portfolio that boosts profitability disproportionately to sales volume. As a payer of dividends, the entity offers a dividend yield of 0.6% with a payout ratio of 10.2%. This extremely low payout ratio suggests that the company retains the vast majority of its earnings, prioritizing reinvestment into its vast network of facilities and debt reduction over distributing income to shareholders. The sustainability of the dividend is high given the low payout relative to the robust earnings growth, providing a stable but modest income component to the total return profile. Overall, the growth and income profile is defined by aggressive earnings expansion supported by a conservative dividend policy that allows for substantial internal capital generation and operational scaling.